US Senators consider legislation to end pharma pay-for-delay deals

Pharmaceutical companies may no longer be able to secure pay-off deals to gain exclusivity in the American market with US senators considering a legislation.

The bid follows Thursday’s release of a Federal Trade Commission report documenting a significant rise in the number of so-called “pay-for-delay” agreements that smother competition in the massive drug industry.


Read the source article at MedicalBoox

About the Author

Leave a Reply